- Q1 2024 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024€1.13 (+2.07%)Earnings
- Q4 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2024€1.35 (+1.35%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2023€0.7692 (-0.57%)Earnings
- Rigel Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Q2 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 01, 2023€1.23 (+3.92%)Earnings
- Rigel Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 02, 2023€1.02 (+1.90%)Earnings
- Q4 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2023€1.4 (-3.99%)Earnings
- Rigel Pharmaceuticals Inc To Discuss The FDA Approval of REZLIDHIA Call TranscriptDec 01, 2022
- Q3 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022€0.6948 (+1.12%)Earnings
- Q2 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 02, 2022€1.15 (-1.11%)Earnings
- Rigel Pharmaceuticals Inc to Discuss FORWARD Study Results TranscriptJun 08, 2022
- Q1 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 03, 2022€2.3 (+2.72%)Earnings
- Q4 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2022€2.22 (+0.82%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Q3 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2021€3.02 (+1.51%)Earnings
- Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2021€3.13 (-6.92%)Earnings
- Rigel Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 18, 2021
- Q1 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2021€2.85 (+0.96%)Earnings
- Rigel Pharmaceuticals Inc Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 -Corporate Call TranscriptApr 13, 2021
- Q4 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 02, 2021€3.66 (+3.39%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020€2.32 (+3.57%)Earnings
- Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual)- Panel: State of Play for COVID-19 Therapeutics TranscriptSep 09, 2020
- Q2 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2020€1.98 (+3.13%)Earnings
- Rigel Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 14, 2020
- Q1 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2020€1.75 (+6.06%)Earnings
- Q4 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2020€1.95 (-0.51%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2019€1.9 (-2.06%)Earnings
- Rigel Pharmaceuticals Inc Investor and Analyst Call TranscriptOct 23, 2019
- Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
- Q2 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2019€1.87 (+1.08%)Earnings
- Q1 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2019€2.1 (+2.44%)Earnings
- Q4 2018 Rigel Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2019€1.95 (+1.04%)Earnings
Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference Transcript
Let's kick it off. So welcome back everyone for Day 2 of the Citi Biotech Conference. It's my great pleasure to have with me 3 distinguished management members: from Apellis, the CEO, Cedric Francois; from Editas Medicine, Charlie Albright, the Chief Scientific Officer; and of course, in the middle Raul Rodriguez, the President and CEO of Rigel Pharmaceuticals. So welcome all of you. Thanks for participating.
Questions & Answers
So maybe just to kick off, it would be very helpful since your -- I titled this benign hematology, but there's slight differences in the therapeutic focuses for all 3 of your companies. So maybe it would be helpful just to start out giving us a sense of the unmet need in PNH, in ITP and then in the hemoglobinopathies, beta thal and sickle cell just at a high level, that would be perfect.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)